FENNEC PHARMACEUTICALS INC. R&D Expense

Quick Answer

FENNEC PHARMACEUTICALS INC. reported R&D Expense of $250.0 thousand for fiscal year 2025.

FENNEC PHARMACEUTICALS INC. R&D Expense — Annual History

Fiscal Year R&D Expense YoY Change
2025 $250.0K -18.6%
2024 $307.0K +448.2%
2023 $56.0K -98.4%
2022 $3.53M -29.1%
2021 $4.98M -2.4%
2020 $5.11M -9.0%
2019 $5.61M +12.0%
2018 $5.01M +158.7%
2017 $1.94M +310.2%
2016 $472.0K +84.4%
2015 $256.0K -28.3%
2014 $357.0K

Quarterly R&D Expense

Quarter Ending R&D Expense YoY QoQ
September 30, 2025 $29.0K -70.1% -72.9%
June 30, 2025 $107.0K -31.8% +13.8%
March 31, 2025 $94.0K +3033.3% -3.1%
September 30, 2024 $97.0K +708.3% -38.2%
June 30, 2024 $157.0K +1862.5% +5133.3%
March 31, 2024 $3.0K -25.0% -75.0%
September 30, 2023 $12.0K -98.6% +50.0%
June 30, 2023 $8.0K -99.3% +100.0%
  • FENNEC PHARMACEUTICALS INC. showed a decrease of -18.6% in R&D Expense compared to the prior fiscal year.
  • Over the 2014–2025 period, FENNEC PHARMACEUTICALS INC.’s r&d expense has declined by 30.0% (from $357.0 thousand to $250.0 thousand).
  • The most recent figure is from FENNEC PHARMACEUTICALS INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 27, 2026.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment